In vivo chemogenetic RNA editing of macrophages by bioengineered viruses for sepsis treatment

1. Gyawali, B., Ramakrishna, K. & Dhamoon, A. S. Sepsis: The evolution in definition, pathophysiology, and management. SAGE Open Med. 7, 2050312119835043 (2019).

   Google Scholar 

2. Rudd, K. E. et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet 395, 200–211 (2020).

   Google Scholar 

3. Hsu, C. G., Li, W., Sowden, M., Chavez, C. L. & Berk, B. C. Pnpt1 mediates NLRP3 inflammasome activation by MAVS and metabolic reprogramming in macrophages. Cell Mol. Immunol. 20, 131–142 (2023).

   Google Scholar 

4. Fu, J. & Wu, H. Structural mechanisms of NLRP3 inflammasome assembly and activation. Annu. Rev. Immunol. 41, 301–316 (2023).

   Google Scholar 

5. Swanson, K. V., Deng, M. & Ting, J. P. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat. Rev. Immunol. 19, 477–489 (2019).

   Google Scholar 

6. Liang, S. et al. GITR exacerbates lysophosphatidylcholine-induced macrophage pyroptosis in sepsis via posttranslational regulation of NLRP3. Cell Mol. Immunol. 21, 674–688 (2024).

   Google Scholar 

7. Lan, J., Xu, B., Shi, X., Pan, Q. & Tao, Q. WTAP-mediated N(6)-methyladenosine modification of NLRP3 mRNA in kidney injury of diabetic nephropathy. Cell Mol. Biol. Lett. 27, 51 (2022).

   Google Scholar 

8. Konermann, S. et al. Transcriptome engineering with RNA-targeting type VI-D CRISPR effectors. Cell 173, 665–676.e614 (2018).

   Google Scholar 

9. Li, B. et al. Supramolecular genome editing: Targeted gelivery and endogenous activation of CRISPR/Cas9 by dynamic host-guest recognition. Angew. Chem. Int. Ed. Engl. 63, e202316323 (2024).

   Google Scholar 

10. Yan, X., Pan, Q., Xin, H., Chen, Y. & Ping, Y. Genome-editing prodrug: Targeted delivery and conditional stabilization of CRISPR-Cas9 for precision therapy of inflammatory disease. Sci. Adv. 7, eabj0624 (2021).

    Google Scholar 

11. Qing, S. et al. Biomineralized bacterial outer membrane vesicles potentiate safe and efficient tumor microenvironment reprogramming for anticancer therapy. Adv. Mater. 32, e2002085 (2020).

    Google Scholar 

12. Kang, W. S. et al. A macrophage-specific synthetic promoter for therapeutic application of adiponectin. Gene Ther. 21, 353–362 (2014).

    Google Scholar 

13. Zheng, X. et al. Combination therapy with resveratrol and celastrol using folic acid-functionalized exosomes enhances the therapeutic efficacy of sepsis. Adv. Healthc. Mater. 12, 2301325 (2023).

    Google Scholar 

14. Fan, L. et al. Exosome-based mitochondrial delivery of circRNA mSCAR alleviates sepsis by orchestrating macrophage activation. Adv. Sci. 10, 2205692 (2023).

    Google Scholar 

15. Chen, W. et al. Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis. Nat. Rev. Cardiol. 19, 228–249 (2022).

    Google Scholar 

16. Yang, Y. et al. Targeted silver nanoparticles for rheumatoid arthritis therapy via macrophage apoptosis and Re-polarization. Biomaterials 264, 120390 (2021).

    Google Scholar 

17. Zhou, X. et al. Targeted therapy of rheumatoid arthritis via macrophage repolarization. Drug Deliv. 28, 2447–2459 (2021).

    Google Scholar 

18. Zhang, W. et al. Intratonsillar immunotherapy: a convenient and effective alternative to subcutaneous immunotherapy for allergic rhinitis. Research 8, 0581 (2025).

    Google Scholar 

19. Han, R. et al. Folic acid-modified ginger-derived extracellular vesicles for targeted treatment of rheumatoid arthritis by remodeling immune microenvironment via the PI3K-AKT pathway. J. Nanobiotechnol. 23, 41 (2025).

    Google Scholar 

20. Vande Walle, L. & Lamkanfi, M. Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets. Nat. Rev. Drug Discov. 23, 43–66 (2024).

    Google Scholar 

21. Kayagaki, N. et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature 526, 666–671 (2015).

    Google Scholar 

22. Liu, Q. et al. GSNOR negatively regulates the NLRP3 inflammasome via S-nitrosation of MAPK14. Cell Mol. Immunol. 21, 561–574 (2024).

    Google Scholar 

23. Maji, B. et al. Choudhary, Multidimensional chemical control of CRISPR-Cas9. Nat. Chem. Biol. 13, 9–11 (2017).

    Google Scholar 

24. Dejager, L., Pinheiro, I., Dejonckheere, E. & Libert, C. Cecal ligation and puncture: the gold standard model for polymicrobial sepsis? Trends Microbiol. 19, 198–208 (2011).

    Google Scholar 

25. Ugan, R. A. et al. Cadirci, Possible contribution of the neprilysin/ACE pathway to sepsis in mice. Life Sci. 258, 118177 (2020).

    Google Scholar 

26. Van der Poll, T., Shankar-Hari, M. & Wiersinga, W. J. The immunology of sepsis. Immunity 54, 2450–2464 (2021).

    Google Scholar 

27. Wang, B. et al. Sepsis induces non-classic innate immune memory in granulocytes. Cell Rep. 42, 113044 (2023).

    Google Scholar 

28. Cox, D. B. T. et al. RNA editing with CRISPR-Cas13. Science 358, 1019–1027 (2017).

    Google Scholar 

29. Özcan, A. et al. Programmable RNA targeting with the single-protein CRISPR effector Cas7-11. Nature 597, 720–725 (2021).

    Google Scholar 

30. Rodda, L. B. et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. Cell 184, 169–183 (2021).

    Google Scholar 

31. Moiani, A. et al. Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts. J. Clin. Invest. 122, 1653–1666 (2012).

    Google Scholar 

32. Yin, D. et al. Targeting herpes simplex virus with CRISPR-Cas9 cures herpetic stromal keratitis in mice. Nat. Biotechnol. 39, 567–577 (2021).

    Google Scholar 

33. Yin, D. et al. Dendritic-cell-targeting virus-like particles as potent mRNA vaccine carriers. Nat. Biomed. Eng. 9, 185–200 (2025).

    Google Scholar 

34. Wang, H. et al. Interrogation of folic acid-functionalized nanomedicines: The regulatory roles of plasma proteins reexamined. ACS Nano 4, 14779–14789 (2020).

    Google Scholar 

35. Zhao, L. et al. Exploration of CRISPR/Cas9-based gene editing as therapy for osteoarthritis. Ann. Rheum. Dis. 78, 676–682 (2019).

    Google Scholar 

36. Cullis, P. R. & Felgner, P. L. The 60-year evolution of lipid nanoparticles for nucleic acid delivery. Nat. Rev. Drug Discov. 23, 709–722 (2024).

    Google Scholar 

37. Kalluri, R. & LeBleu, V. S. The biology, function, and biomedical applications of exosomes. Science 367, eaau6977 (2020).

    Google Scholar 

38. Lu, S. et al. Pyroptosis-responsive microspheres modulate the inflammatory microenvironment to retard osteoporosis in female mice. Nat. Commun. 16, 8127 (2025).

    Google Scholar 

39. Zhang, G. et al. Artificial mucus layer formed in response to ROS for the oral treatment of inflammatory bowel disease. Sci. Adv. 10, eado8222 (2024).

    Google Scholar 

40. Wick, K. D. et al. Promises and challenges of personalized medicine to guide ARDS therapy. Crit. Care 25, 404 (2021).

    Google Scholar 

41. Lee, D. et al. Population analysis of the Korean native duck using whole-genome sequencing data. BMC Genomics 21, 216 (2020).

    Google Scholar 

Download references

Author notes

1. These authors contributed equally: Wensong Xi, Youcui Xu.

Authors and Affiliations

1. State Key Laboratory of Macromolecular Drugs and Large-scale Preparation, Hefei Center; School of Pharmacy, Anhui Medical University, Hefei, China

   Wensong Xi, Youcui Xu & Yuan Ping

2. Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China

   Wensong Xi, Xiaojie Yan & Yuan Ping

3. College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China

   Wensong Xi, Weiwei Bao, Zhixing Ding, Hu Xiao, Jiamin Yang, Xiaojie Yan & Yuan Ping

4. Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Institute of Innovative Drugs, Research and Industrialization of New Drug Release Technology Joint Laboratory of Anhui Province, School of Pharmacy, Anhui Medical University, Hefei, China

   Youcui Xu

Contributions

X.Y. and Y.P. conceived the project and designed experiments. W.X., Y.X., X.Y., W.B., Z.D., H.X., and J.Y. performed the experiments. X.Y. and H.X. constructed and verified the plasmids. W.X. and Y.X., X.Y. analyzed the data and wrote the manuscript. X.Y. and Y.P. supervised the project and wrote the manuscript.

Corresponding authors

Correspondence to Xiaojie Yan or Yuan Ping.

Competing interests

The Authors declare the following competing interests: A patent application related to the biomineralized lentivirus platform described in this work has been filed with the China National Intellectual Property Administration by Zhejiang University, with W.X. and Y.P. as inventors (application number CN202211558965.3). The remaining authors declare no competing interests.

Peer review information

Nature Communications thanks Yilai Shu and Jun Wang for their contribution to the peer review of this work. A peer review file is available.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions